Management is pivoting to a high-growth strategy by expanding sales capacity in priority geographies that exhibit favorable market access and established distributor relationships.Oncology performance remained a stable revenue base, with CINVANTI showing resilience against competitive pressures while the company continues the planned wind-down of SUSTOL.The implementation of permanent J-Codes for ZYNRELEF and APONVIE has improved reimbursement clarity, facilitating broader adoption across hospitals and ambu ...